High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.

doi:10.1158/1541-7786.MCR-21-0053

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.

Molecular cancer research : MCR - 1 Sept 2021

Lee Chung-Han, DiNatale Renzo G, Chowell Diego, Krishna Chirag, Makarov Vladimir, Valero Cristina, Vuong Lynda, Lee Mark, Weiss Kate, Hoen Doug, Morris Luc, Reznik Ed, Murray Samuel, Kotecha Ritesh, Voss Martin H, Carlo Maria I, Feldman Darren, Sachdev Pallavi, Adachi Yusuke, Minoshima Yukinori, Matsui Junji, Funahashi Yasuhiro, Nomoto Kenichi, Hakimi A Ari, Motzer Robert J, Chan Timothy A

Abstract excerpt

Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have improved the clinical benefit achieved by ICB monotherapy and have revolutionized RCC treatment. While biomarkers like PD-L1 and tumor mutational burden (TMB) are FDA approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Renal Cell

Share to HLA Antigens

Share to Kidney Neoplasms

Share to Phenylurea Compounds

Share to Quinolines

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 34039647
DOI: 10.1158/1541-7786.MCR-21-0053
PMCID: PMC8419018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.PMID 34039647Read ↗

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.Semantic proximity Read ↗

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.Semantic proximity Read ↗

Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escapeSemantic proximity Read ↗

Spatiotemporal evolution of the ccRCC microenvironment links intra-tumoral heterogeneity to immune escapeSemantic proximity Read ↗

HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.Semantic proximity Read ↗

Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint InhibitorsSemantic proximity Read ↗

VHL mutations predict survival of patients with renal cell carcinoma in response to the therapy of immune checkpoint inhibitorsSemantic proximity Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

Quantification of T- and B-cell immune receptor distribution diversity characterizes immune cell infiltration and lymphocyte heterogeneity in clear cell renal cell carcinomaSemantic proximity Read ↗

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.Semantic proximity Read ↗

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.